Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies among Medicare Beneficiaries: An Analysis from the Medicare Part D Database

Medicine & Life Sciences

• Medicare Part D 100%
• Medicare 66%
• LDL Cholesterol 58%
• Names 45%
• Costs and Cost Analysis 39%
• Databases 38%
• Proprotein Convertase 9 35%
• Ezetimibe 33%
• Hydroxymethylglutaryl-CoA Reductase Inhibitors 23%
• Prescription Drugs 18%
• Health Expenditures 16%
• Drug Utilization 10%
• Therapeutics 10%
• Drug Costs 9%
• Datasets 6%
• Cardiovascular Diseases 5%
• Health Care Outcome Assessment 5%
• Cross-Sectional Studies 5%
• Pharmaceutical Preparations 3%